Trial · NCT01030718
Results by group88
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 88
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuation | CML - Chronic Phase (CML-CP) | AEs (symptoms/signs and laboratory abnormalities) | 30 | participants | |
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuation | CML - Accelerated Phase and Blast Phase (CML-AP/BP) | AEs (symptoms/signs and laboratory abnormalities) | 11 | participants | |
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuation | Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL) | AEs (symptoms/signs and laboratory abnormalities) | 13 | participants | |
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuation | CML - Chronic Phase (CML-CP) | SAEs (symptoms/signs and laboratory abnormalities) | 13 | participants | |
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuation | CML - Accelerated Phase and Blast Phase (CML-AP/BP) | SAEs (symptoms/signs and laboratory abnormalities) | 9 | participants | |
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuation | Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL) | SAEs (symptoms/signs and laboratory abnormalities) | 11 | participants | |
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuation | CML - Chronic Phase (CML-CP) | Deaths | 1 | participants | |
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuation | CML - Accelerated Phase and Blast Phase (CML-AP/BP) | Deaths | 2 | participants | |
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuation | Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL) | Deaths | 3 | participants | |
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuation | CML - Chronic Phase (CML-CP) | AEs that led to discontinuation | 4 | participants | |
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuation | CML - Accelerated Phase and Blast Phase (CML-AP/BP) | AEs that led to discontinuation | 7 | participants | |
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuation | Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL) | AEs that led to discontinuation | 4 | participants | |
| Participants With Chronic Phase CML (CML-CP): Percentage of Participants With Cytogenetic Response | CML - Chronic Phase (CML-CP) Total | Major cytogenetic response (MCyR) | 77 | 95% Confidence Interval 57.7 to 90.1 | Percentage of Participants |
| Participants With Chronic Phase CML (CML-CP): Percentage of Participants With Cytogenetic Response | CML - Chronic Phase (CML-CP) - Imatinib Resistant | Major cytogenetic response (MCyR) | 61 | 95% Confidence Interval 35.7 to 82.7 | Percentage of Participants |
| Participants With Chronic Phase CML (CML-CP): Percentage of Participants With Cytogenetic Response | CML - Chronic Phase (CML-CP) - Imatinib Intolerant | Major cytogenetic response (MCyR) | 100 | 95% Confidence Interval 73.5 to 100.0 | Percentage of Participants |
| Participants With Chronic Phase CML (CML-CP): Percentage of Participants With Cytogenetic Response | CML - Chronic Phase (CML-CP) Total | Complete cytogenetic response (CCyR) | 63 | 95% Confidence Interval 43.9 to 80.1 | Percentage of Participants |
| Participants With Chronic Phase CML (CML-CP): Percentage of Participants With Cytogenetic Response | CML - Chronic Phase (CML-CP) - Imatinib Resistant | Complete cytogenetic response (CCyR) | 44 | 95% Confidence Interval 21.5 to 69.2 | Percentage of Participants |
| Participants With Chronic Phase CML (CML-CP): Percentage of Participants With Cytogenetic Response | CML - Chronic Phase (CML-CP) - Imatinib Intolerant | Complete cytogenetic response (CCyR) | 92 | 95% Confidence Interval 61.5 to 99.8 | Percentage of Participants |
| Participants With CML-Accelerated or Blast Phase (AP/BP): Percentage of Participants With Cytogenetic Response | CML-AP/BP - Total Cohort | Major cytogenetic response (MCyR) | 27 | 95% Confidence Interval 6.0 to 61.0 | Percentage of Participants |
| Participants With CML-Accelerated or Blast Phase (AP/BP): Percentage of Participants With Cytogenetic Response | CML-AP/BP - Imatinib Resistant | Major cytogenetic response (MCyR) | 38 | 95% Confidence Interval 8.5 to 75.5 | Percentage of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01030718/results